Premium Iohexol API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Iohexol (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Non-Ionic Radiographic Contrast Agent

Indications: Diagnostic Imaging (Angiography, Urography, Myelography, CT Enhancement)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Iohexol distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Iohexol is a highly specialized, water-soluble Active Pharmaceutical Ingredient (API). In clinical pharmacology, it is classified as a non-ionic, low-osmolar radiographic contrast medium (LOCM). For pharmaceutical manufacturers focused on expanding their diagnostic imaging portfolios, this API is a foundational raw material for modern radiology suites.

The mechanism of action for Iohexol relies entirely on its physical and elemental properties rather than receptor binding. The molecule is structured around a central benzene ring that carries three heavy iodine atoms. When formulated into a sterile solution and introduced into the body—either intravascularly, intrathecally, or enterally—these iodine atoms effectively absorb X-ray radiation.

As X-rays pass through the patient, the presence of Iohexol creates a profound density gradient between the target vessels, organs, or cavities and the surrounding soft tissues. This mechanism enables precise, high-resolution visualization of internal structures during computed tomography (CT) scans, fluoroscopy, and traditional radiography.

For pharmaceutical formulation scientists, integrating this API allows for the development of safer diagnostic injectables. Because Iohexol is non-ionic, it does not dissociate in water, resulting in a significantly lower osmolality compared to older ionic contrast media. This drastically reduces chemotoxicity, vascular pain upon injection, and the overall incidence of adverse patient reactions.

Sourcing Iohexol in Pakistan: Morgan’s Supply Network

Manufacturing contrast media requires handling massive volumes of active ingredients. Procuring bulk diagnostic APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Iohexol Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan supplies commercial-scale (tonnage) and pilot-scale quantities sourced from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines, with facilities routinely undergoing rigorous WHO prequalification and compliance audits. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard R&D batch or are scaling up a high-volume Iohexol api Pakistan procurement order for continuous production, we help ensure that your commercial batch schedules are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, tightly controlled bioburden limits, and predictable physical properties for critical downstream processing.

Technical Specifications for QA & R&D

The Iohexol API supplied by Morgan undergoes exacting analytical testing at the source to meet current USP and Ph. Eur. pharmacopeial standards.

• Chemical Name: 5-[N-(2,3-dihydroxypropyl)acetamido]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
• CAS Number: 66108-95-0
• Appearance: White to off-white, highly hygroscopic powder
• Molecular Formula: C19H26I3N3O9
• Molecular Weight: 821.14 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Freely soluble in water. Detailed solubility parameters and specific gravity data across various aqueous concentrations are documented in the technical data sheet to assist your formulation teams with viscosity and osmolality profiling.

Manufacturing and Handling Guidelines for Formulators

Iohexol is administered in exceptionally large doses compared to standard therapeutics (often exceeding 100 grams of API per patient during a single procedure). Consequently, facilities processing this API must enforce strict sterility and endotoxin controls on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, highly moisture-resistant containers. Maintain strict climate-controlled conditions (controlled room temperature, rigorously protected from ambient humidity and direct light) to prevent the highly hygroscopic powder from clumping and degrading.
• Sterile Manufacturing Requirements: Contrast media are large-volume parenterals. While the raw API powder handling requires standard industrial PPE (respirators, nitrile gloves, protective facility garments), the actual compounding and filling stages must be executed in advanced aseptic environments (Grade A/B cleanrooms). Formulators must employ validated sterile filtration (0.22-micron) and terminal sterilization (autoclaving) protocols, paying critical attention to controlling bioburden and bacterial endotoxins throughout the entire compounding lifecycle.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.